Note: Descriptions are shown in the official language in which they were submitted.
33S3
- 1 - O.Z. 0050/38380
Preparation of solid pharmaceutical forms
~ ~ ~ .
The present invent;on relates to a process for
the preparation of solid pharmaceutical forms, which con-
tain an n-vinylpyrrol;d-2 one(NVP) polymer as a binder,
by injection molding or extrusion and shaping.
Conventional tabletting mach;nes operate by a cyc-
lic process us;ng punches and d;es. The process requires
thoroughly premixed and specially prepared tabletting
materials and the overall process is therefore a multi-
stage one and is expens;ve. The production of solidpharmaceutical forms with controlled release of active
compound is particularly expensive. This may require
retardation measures on the one hand and measures for im-
proving the absorption of active compounds on the other
hand.
One possible method for improving the absorption
of spar;ngly soluble act;ve compounds ;s to use solid
solut;ons of the active compounds in ~atPr-soluble poly-
mers. The known solid solutions of this type in NVP
poLymers were prepared by dissolving the active compound
and the poLymer together in an organic solvent and re-
moving the latter. As a rule, in order to dissolve both
the hydrophobic compound and the hydrophilic polymer,
chlorohydrocarbons were required. Complete removal of
these solvents is very expensive. In order to avoid en-
v;ronmental pollut;on, the solvents must aga;n be re-
moved as completely as poss;ble from the waste air, wh;ch
;n turn ;s very expens;ve. Processes of this type are
described in, for example~ U.S. Patent 3,089,818; T.
Tachibana and A. Nakamura, Kolloid ~e;tschrift and
Zeitschrift fur Polymere, 203 (1965), 130; Japanese Patent
24,379; M. Mayersohn et al., J. Pharm. Sci. 55 ~1966),
1323; DE-B-11 37 009; and W. Scholten, Arzn. Forschung 14
(1964), 469.
The extrusion of active compound/polymer mixtures
has already been described (cf. for example DE-A-12 29 248;
P. Speiser, Pharmaceutica Acta Helv., 41 (1966), 340 and
3S3
- 2 - o.Z~ 0050/38380
ibid. 46 (1971, 31). However, in no case were solvent-
free NVP polymers melted, let alone extruded, without
being mixed with other polymers or with water, and in no
case is the formation of a so~id solution of a spar;ngly
S water-soluble active compound in a water-soluble polymer
described.
In R. Voigt, Lehrbuch der pharmazeutischen
Technologie~ 5th Edition, Verlag Chemie, We;nheim, 1984,
pages 221 - 222, the preparation of solid pharmaceutical
formulations by injection molding or extrusion shaping of
active compound/thermoplastic mixtures is described in
general form but without any specific information, in par-
ticular about the type of polymers which are suitable for
this purpose. The polymers in question here were without
a doubt not highly hydrophilic polymers, such as NVP poly-
mers, since, in the pharmaceutical sec~or to date, these
have been processed not via the dry melt but always as a
base with salvents (as a rule water) (cf~ for example,
~ritish Patent 1,388,786).
Z0 It ;s an object of the present invention to pro-
vide a simple process for the preparation of solid pharma-
ceutical forms, preferably with controlled release of ac-
tive compound.
We have found that this object is achieved by a
process for the preparation of solid pharmaceutical forms
by mixing one or more pharmaceutical active compounds with
one or more fusible, pharmacologically tolerated binders
and, if required, other conventional pharmaceutical aux-
iliaries, at from S0 to 180C, preferably from 60 to
160C, and subjecting the mixture to injection molding or
extrusion ancl shaping, wherein the fusible binder used is
a solvent-free NVP polymer which has a water content of
not more than 3.5% by weight and contains not less than
20, preferably not less than 60, in particular 100, ~ by
weight of NVP as copolymerized units, and, where they are
present, all of whose comonomers contain nitrogen and/or
oxygen, and, at least when the glass transition
353
- 3 - O.Z. 3050/38380
temQerature of the mixture is above 120C, an NVP polymer
is used which is obtained by Polymerization ;n an organic
solvent or using an organic peroxide as an initiator in
a~ueous solution, and the mixture dbes not conta;n any
thermoplastics which are sparingly soluble ;n gastric
juice (less than 10~ dissolving ir, 6 hours~.
The NVP polymers should contain not less than
20, preferably not less than 60, in particular 100, %
by weight of NVP as copolymerized units and have a
Fikentscher K value (Cellulose-Chemie 13 (1932), 58 -
64 and 71 - 74) of from 10 to 70, preferably from 10 to
5~, particularly preferably.from 12 to 43, in particular
from 12 to 35 and, in the case of NVP homopolymers,
preferably from 12 to 35, in particular from 12 to 17~
The polymeric binder must soften or melt in the
total m;xture of all components at from 50 to 180C,
preferably from 60 to 130C, so that the melt can be
extruded. The glass transition temperature of the mix-
ture must therefore in any case be less than 180C~ pref-
~0 erably less than 130Cu If necessary, it is reduced by
conventional pharmacologically acceptable plasticizers,
such as long-chain alcohols, ethylene glycol, propylene
glycol, trimethylolpropane, triethylene gylcol, butane-
diols, pentanols, hexanols, polyethylene glycols, aro-
Z5 matic carboxylates (eg. dialkyl phthalates, trimellitates,benzoates or terephthalates), aliphatic dicarboxylates
teg. dialkyl adipates, sebacates, azeleates, citrates or
tartrates) or fatty acid esters. The plasticizer pref-
erably accounts for no more than 20% by weight, based on
the polymer. Particularly preferred NVP polymers are
those which do not require additives of this type, ie.
those which~ as a mixture with the active ;ngredient and,
if required, conventional pharmaceùtical aux;liaries, melt
ûr soften in the desired temperature range even without
additives having a specific plasticizing effect. Melt-
ing or softening below a certain temperature may be
necessary because of possible thermal and/or ox;dat;ve
~3~133~i3
- 4 - O.Z. 0050/38380
damage not only to the active ingredient but also to the
NVP polymer. The latter may undergo yellowing on extru-
sion, and it is for this reason that NVP polymers have
not usually been extruded to date. However, there is
l;ttle danger at extrusion temperatures below 180C,
especially below 130C, if the polymer has not been pre-
pared in aqueous solution using hydrogen peroxide as an
initiator, but has been obtained in an organic solvent
or in water using an organic peroxide as an initiator,
for example by the process according to German Patent
Application P 36 4Z 633.4 or by the process described in
U.S. Patents 4,5Z0,179 and 4,520,180.
If the K value is greater than 17, in particular
greater than 30 or even 40 (up to a maximum of 70), and
no highly plasticizing component is present, the only
suitable copolymers are those having a glass transition
temperature Tg of less than 1Z0C, preferably less than
100C, or the NVP polymer (including homopolymers) must
not have been prepared in water containing ~22 as an ini-
tia~or. This would give rise to polymer terminal groupswhich result in yellowing at elevated ~emperatures~
~ u;table comonomers are unsaturated carboxylic
acids, eg. methacrylic acid, crotonic acid, maleic acid
and itaconic acid, and their esters with alcohols of 1 to
12, preferably 1 to 8, carbon atoms, as well as hydroxy-
ethyl or hydroxypropyl acrylate and methacrylate, (meth)
acrylamide, the anhydrides and half esters of maleic acid
and itaconic acid (the half esters preferably not being
formed until after the polymerization), N-vinylcaprolactam
and vinyl propionate.
Preferred comonomers are acrylic acid and in par-
ticular vinyl acetate. Preferred NVP polymers are there-
fore those which either contain only NVP or vinyl acetate
as the only comonomer or contain not less than 10, pref-
erably not less than 30% by weight thereof as copolymer-
ized units. Some or all of the vinyl acetate and vinyl
propionate may be hydrolysed after the polymerization~
3~;i3
- 5 - O.Z. 0050/38380
Solvent-free means that no organic solvent, in
particular no chlorohydrocarbon, is added. Furthermore,
thermoplastics which are poorly soluble in gastric juice
should not be admixed, and the water content sf the NVP
polymer should not exceed 3.5% by weight. (This water
content is due to spontaneous absorption of moisture from
the air and not the inten-tional addition of ~ater.)
Higher water contents are harmful in that evaporation of
the water after the polymer/active compound extrudate
emerges from the die results in porous moldings or may
even produce moldings possessing cracks in the surface.
The novel process is suitable, for example, for
processing the following active compounds: betamethasone,
thiotic acid, sotalol, salbutamol, norfenefrine, sily-
lS marin, dihydroergotamine, buflomedil, etofibrate, indo-
metacin, oxazepam, ~-acetyl-digoxin, piroxicam, haloper-
idol, ISMN, amitriptylin, d;clofenac, nifedipine, vera-
pamil, pyritinol~ nitrendipin, doxycycline, bromhexine,
methylprednisolone, clonidine, fenofibrate, allopurinol,
pirenzepine, levothyroxin, tamoxifen, metildigoxin, o~(3-
hydroxyethyl)-rutoside, propicillin, aciclovir mono-
nitrate, paracetamol, naftidrofuryl, pentoxifylline, pro-
pafenone, acebutolol, L-thyroxin, tramadol, bromocriptine,
loperamide, ketotifen, fenoterol, cadobelisate, propanolol,
minocycline, nicergoline, ambroxol, metoprolol, ~-sito-
sterol, enalaprilhydrogen maleate, bezafibrate, ISDN, gallo-
pamil, xantlnol nicotinate, digitoxin, flunitrazepam, ben-
cyclane, dexapanthenol, pindolol, lorazepam, diltiazem,
piracetam, phenoxymethyl-pencillin, furosemide, bromazepam,
flunarizin, erythromycin, metoclopramide, acemetacin, rani-
tidin, biperiden, metamizole, doxepin, dipotassium chloro-
azepate, tetrazepam, estramustine phosphat, terbutaline,
captopril, maprotiline, prazosin, atenolol, glibenclamide,
cefaclor, etilefrine, cimetidine, theophylline, hydromor-
phone, ibuprofen, primidone, clobazam, oxaceprol, medroxy-
progesterone, flecainid, mgpyridoxal 5-phosphate glutami-
nate, hymechromone, etofylline clofibrate, vincamine,
35~
- 6 - O.Z. OC50/38380
cinnarizine, diazepam, ketoprofen, fluPentixol, molsi-
mine, glibornuride, dimetinden, melperone, soquinolol,
dihydrocodeine, clomethiazole, clemas~ine, glisoxepide,
kallid;nogenase, oxyfedrine, baclofen, carboxymethyl-
cysteine, thioridazine, betahistine, L-tryptophan, myrtol,
bromelaine, prenylamine, salazosulfapyridine, astemizol,
sulpiride, b.enzerazide, dibenzepine,acetylsalicylic acid,
miconazol, nystatin, ketoconazole, Na picosulfate, cole-
styramine, gemfibrocil, rifampicin, fluocortolone, mex-
iletin, amoxicillin, terfenadrin, mucopolysaccharidepolysulfate, triazolam, mianserin, tiaprofenic acid,
amezinium metilsulfate, mefloquine, probucol, quinidine,
carbamazepine, mg L-aspartate, penbutolol, piretanide,
amitriptyline, cyproterone, Na valpro;nate, mebeverine,
bisacodyl, 5-aminosalicylic acid, dihydralazine, magal-
drate, phenprocoumon, amantadine, naproxen, carteolol,
famotid;ne, methyldopa, auranofine, estriol, nadolol,
levomepromazine, doxorubicin, medofenoxate, azathioprine,
flutamide, norfloxacin, fendiline, prajmalium bitartrate
2Q and aescin.
Solid solutions of the following active compounds
are particularly preferred: acetaminophen (paracetamol),
acetohexamide, acetyldigoxin, acetylsalicylic acid, acro-
mycin, anipamil, benzocaine, ~-carotene, chloramphenicol,
chlordiazepoxide, chlormadinone acetate, chlorothiazide,
cinnarizine, clonazepam, codeine, dexamethasone, diazepam,
dicoumarol, digitoxin, digoxin, dihydroergotamine, drota-
verine, flunitrazepam, furosemide, gramicidin, griseofulvin,
hexobarbital, hydrochlorothiazide, hydrocortisone, hydro-
fluormethiazide, indomethacin, ketoprofen, lonetil, medaze-
pam, mefruside, methandrostenolon e, methylprednisolone,
methylsulfadiazine (sulfaperin), nalidixic acid, nifedi-
pine, nitrazepam, nitrofurantoin, nystatin, estradiol,
papaverine, phenacetin, pheno-barbital, phenylbutazone,
phenytoin, predni-sone, reserpine, spironolactone, strepto-
mycin, sulfadimidine (sulfamethazine), sulfamethizole,
sulfamethoxazole, sulfamethoxydiazine (sulfameter),
133~
- 7 - O.Z. 0050/38380
sulfaperin, sulfathiazole, sulfisoxazole, testosterone,
tolazamide, tolbutamide, trimethoprim and tyrothricin.
The term solid solutions is familiar to the skil-
led worker, for example from the literature cited at the
outset. In solid solutions of pharmaceutical active
compounds in polymers, the active compound is present
in the polymer in molecular disperse form.
The formation of solid solutions of the stated ac-
tive compounds in NVP polymers was not to be foreseen and
is all the more surprising since many active compounds
which are sparingly soluble in water do not form (mole-
cular disperse) solid solutions in other polymers but
are incorporated in the particular polymer in the form
of solid particles which can be detected under the elec-
tron microscopeu In the case of crystalline active com-
pounds, they also exhibit a Debye-Scherrer pattern, in
contrast to the solid solutions.
If, in addition to the binders emp~oyed according
to the invention, further water-soluble, fusible binders
are used, the amount of the first-mentioned binders
should be not less than 50, preferably not less than 70,
by weight, based on all fusible binders used.
For the purposes of the present invention, solid
pharmaceutical forms are, for example, tablets, tabLet
cores~ granules and suppositories~
For the purposes of the present invention, pharma-
ceutical active compounds are all substances which have a
pharmaceutical effect and have a very low Level of side
effects, provided that they do not decompose under the pro-
cessing conditions. The amount of active compound per dos-
age unit and th~ concentration can vary within w;de limits,
depending on the activity and the rate of release. The
only condition is that they are sufficient for achieving
the desired effect. For example, the cor,centration of
active compound may be from 0.1 to 95, preferably from 20
to 80, in particular from 30 to 70, ~ by weight. Combi-
nations of active compounds may also be used. for the
33S3
- 8 - O.Z. 0050/38380
purposes of the present invention, vitamins too are active
compounds. Active compounds which are sparingly soluble
in water are those ~hose absorption in the gastro intes-
tinal tract is usually unsatisfactory owing to their low
solubility.
The active compound or compounds can be mixed
with the binders and, where relevant, other conventional
pharmaceutical additives be~ore or after melting of the
polymeric binder, by a method conventionally used in in-
dustry. Mixing is preferably carried out in an extruderhaving a mixing zone, preferably a twin-screw extruder, or
in the scre~ zone of an injection molding machine~
Shaping may be effected by injection molding or
by extrusion followed by shaping of the plastic extru-
date, for example by hotface cutting to give granules ormolding to give tablets, for example by passing the
extrudate between two rollers which are driven in op-
posite directions and have depressions opposite one an-
other in the roller shell, the form of these depressions
determining the tablet shape. Cold-face cutting is also
suitabLe and may be followed by pressing of the granules
to give tablets. For the purpose of the present inven-
tion, the extrustion includes injection molding.
~y varying the type and amount of comonomer, the
NVP polymer can, depending on the intended use, be made
sufficiently strongly or weakly hydrophilic for the
tablets prepared from it to dissolve (rapidly or with a
delay) in the mouth (buccal tablets) or in the stomach or
not until they reach the intes~;ne, or to swell so that
they release the active compound. They are sufficiently
s~elLable ~hen they absorb more than 10~ by weight of
water on storage at 90% relative humidity. If it is de-
sirable for carboxyl-containing binders to release the
active compound only when they reach the alkaline medium
of the intestine, the above water absorption applies only
to the neutralized form (salt form) of the polymer (in
which some or all of the protons of the carboxyl grouPs
- 9 - o.Z. 0050/38380
have been replaced by ammonium, sodium or potassium
ions).
E~amples of conventional pharmaceutical auxili-
aries, whose total amount may be up to 100% by weight,
based on the polymer are extenders, such as silicates or
silica, stearic acid or its salts with, for e~ample,
magnesium or calcium, methylcellulose, sodium carboxy-
methylcellulose, talc, sucrose, lactose, cereal or corn
starch, potato flour or polyvinyl alcohol, as well as
wetting agen~s, preservatives, disintegrating agents,
adsorbents, colorants and flavorings (cf. for examPle H.
Sucker et al., Pharmazeutische Technologie, Thieme-Verlag,
Stuttgart 1978).
If desired, the solid pharmaceutical form may also
be provided with a conventional coating to improve the
appearance and/or the flavor (coated tablets) or addition-
ally to delay the release of active compound. For oral
tablets with sustained release of act;ve compound, it may
be advantageous to prepare the tablet by one of the known
techniques in a closed-cell porous form so that it floats
in the stomach and consequently remains there longer.
In the case of solid pharmaceutical forms with
rapid release of active compound, the novel process per-
mits substantially freer design of the pharmaceutical form
than does the conventional tablet pressing technique. Fc,r
example, the tablets can be engraved for designation, or
virtually any shapes, which are clearly identifiable even
by those with impaired vision, may be produced. Certain
shapes, for example hemispheres may also be suitable for
achieving certain characteristics of active compound
release. ~y e~trusion or hot or cold face cutt;ng of the
extrudate, it is possible to produce very small-particled
and uniformly shaped granules in a simple manner, for
example for mult;ple-un;t forms.
In the Examples which follow, parts and
percentages are by weight. The active compound release
time was determined by the half-change test method.
3353
- 10 - O.Z. 0050/38380
EXAMPLE 1
45 parts of a copolymer of 60% by weight of M~
vinylpyrrolidone and 40% by weight of vinyl acetate,
having a K value of 30, S parts of stearyl alcohol and S0
S parts of theophylline were processed to tablet cores in an
injection molding machine at 100C. The tablet cores ob-
tained were stable to mechanical effects and did not show
any abrasion during transportation and packaging~ In the
half-change test (cf. for example R. Voig~, Lehrbuch der
pharmazeut. Technologie, 5th Edit-ion, Verl. Chemie.
Weinheim; Deerfield 9each, FLorida; aasel~ 1984, page
627) in conjunction with the paddle method according to
USP 21, the active compound was comple~ely released in the
course of from 6 to 8 hours.
EXAMPLE Z
S0 parts of the copolymer of example 1 and 50
parts of theophylline were processed to oblong tablets
having a length of 1 cm in an injection molding machine
at 120C. In this case too, the tablets thus obtained
Z0 were stable to mechanical effects and released the ac-
tive compound completely in the course of from 1 to 2
hours.
EXAMPLE 3
47.5 parts of a copolymer of 60% by ~eight of
Z5 N-vinylpyrrolidone and 40% by weight of vinyl acetate,
having a K value of 30, 2.5 parts of crosslinked poly-
vinylpyrrolidone ~PVP) as a tablet disintegrator and S0
parts of theophylline were mixed and extruded in a twin~
screw extruder. The temperature of each of the five shots
was 120C. The die was at 130C. The still plastic
extrudate was pressed to g;ve oblong tablets with the aid
of the apparatus described in the parallel German Appli-
cation P 36 12 211~4. The tablets were stable to mechani-
caL effects and the active compound was reLeased in the
course of from 30 to 45 minutes.
EXAMPLE 4
S0 parts of a copolymer of 30% by weight of N-
~ ~3~)8353
~ O.Z. 0050/38380vinylpyrrolidone and 70% by weight of vinyl acetate,
having a K value of 52, and SO parts of theophylline were
mixed and extruded in a twin-screw extruder. The temp-
eratures of the five shots were 30, 60, 100~ 100 and
S 120C. The die was likewise heated to 1Z0C. The still
plastic extrudate was pressed to give mechanically stable
oblong tablets as described in Example 3. The active
co~pound was completely released in the course of a
hours.
EXAMPLE 5
47.5 parts of a copolymer of bO~ by weight of N-
vinylpyrrolidone and 40% by weight of vinyl acetate,
having a K value of 30, 2.5 parts of stearyl alcohol and
50 parts of theophylline ~ere melted in an injection
molding machine at 100C and processed to table~ cores.
The mold was left at roo0 temperature. The tablet cores
thus produced were stable to mechanical effects, and the
active compound was completely released in the course of 6
hours.
In each of the Examples 6 to 11, a mixture of 50%
by ~eight of an NVP homopolymer (PVP) having a Fikentscher
K value of from 12 to 60 and 50% by weight of theophylline
was processed in a single-screw extruder at the following
temperatures:
Z5 T tC]
~xample K value 1st 2nd 3rd 4th 5th Die
shot
~ . . _
6 12 115 lZ5 135 135 135 145
7 17 125 125 135 145 145 155
8 25 145 155 165 175 175 175
150 160 160 17û 180 180
150 160 160 170 180 180
11 60 80 100 130 140 150 160
The active compound in the tablets thus obt-
tained dissolved completely (in simulated gastric
juice) in tess than 30 minutes in the case of E~amples
6 and 7, in the course of from 1 to Z hours in the case
5~
- 1Z - O~Z. 0050/38380
of Examples 8 and 9, and after more than 2 hours in the
case of Example 10. In Example 11, the PVP contained
10% by weight of stearyl alcohol~ In this case, the time
of release was 8 hours.
EXAMPLES 12 T0 14
36 parts of a copolymer of 60~ by weight of N-
vinylpyrrolidone and 40% by weight of vinyl aceta~e,
having a K value of 30, 4 parts of stearyl alcohol, 40
parts of theophylline and 20 parts of
starch in Example 12,
lactose in Example 13 and
sucrose in Example 14
were mixed in a o-shot twin-screw extruder and shaped
into tablets similarly to Example 1. The temperatures
of the shots were 90, 100, 110, 120, 130 and 13GC, and
the temperature of the die was 135C. The active com-
pound dissolved completely out of the tablets in the
course of 6 hours.
EXAMPLE 15
50 parts of the copolymer of Examples 12 to 14
and 50 parts of lithium carbonate were processed to
tablets on the same apparatus and at the same tempera~
tures as in Examples 1Z to 14. These tablets released
the active compound (in simulated gastric juice) com-
pletely in the course of from 15 to 20 minutes.
EXAMPLE 16
50 parts of the copolymer of Examples 12 to 14 and
50 parts of verapamil were shaped into tablets as des-
cr;bed ;n Examples 12 to 14. The active compound was re-
leased in this case in about 3 hours.
The copolymers used for the preparation of solid
solutions had the follo~ing compositions and K va~ues:
A) 60% by weight of NVP and 40X by ~eight of vinyl
acetate; K value about 33.
~) 100% by weight of NVP; K value 30.
C) 100% by weight of NVP; K value 12.
D) 100% by weight of NVP; K value 12.
' `
33~3
- 13 - O.Z. 0050/38380
The polymers B, C and D were prepared accord-
ing to German Patent Application P 36 42 633.4 in water
using an organic peroxide as the initiator.
EXAMPLE 17
3 parts of copolymer A and 1.5 parts of benzo-
caine were premixed in a plowshare mixer and were
extruded in a simple, 6-shot extruder, the individual
shots having the following temperatures, proceding
toward the die: 30, 30, 40, 50, 60 and 70C. The die
temperature was likewise 70C. The extrudate con-
sisted of a solid solution, as was shown by the Debye-
Scherrer photograph, which did not give the slightest
indication of crystallinity. A similar procedure was
used for the remaining Examples (cf. Table), and the
same result was obtained.
33~i3
1 4- O.Z. DD5ol3a3ao
.
- a
a) ooooooooooooooooou7oooooo~
O U~ N N cn ~ N 19 11~ D 171 0 1'1 0~ ~ N r-- 0 ~ O N ~ _ _
LC~ O O O O O O O O O O O O O O O O O O U~ O O O O O U
11~ N N ~ CO ~ 0 1~ N N O CD Cl~ O ~ O N N 1-')
~ Ooooooocoooooooooomoooooo~
t-- U~ N I~ l N In Itl In U~ n ~ N O 1-- 1-- 0 1~ a~ N N N :J7
~r O O O O O O D O C:l O O O O O O O O 0 0 0 0 0 0 o O ::~
-- ~ N N LD Q N ~n In D O Y7 N N O ~ 1,~7 0 ~D ~ In 1.0 U~ O O O :~
~-. Ooooooooooooooooc:loooooootr~o
O O t~ 1-- 0 ~ ~ O O O D ~D O 1~'1 r-- .~ 0 01 CO 5:1 O~
_ _ V _ . _ _
N
O O O O O 1~ 0 0 0 0 0 0 0 0 ~ O O O O C:~ O O o o o
OOOOOOOOOOOOC:~OOOC~OOOOOOOOO
-- O
o6 ~
~ E r '- ..................................................
1~ _ _ _ _ _ _ _ _ _ _ _ ~ G _ _ _ ~ _ _ _ _ _ _ _
r-l ~rl
C ~3
~ ~ 1 U ~ .2 ~ t Q lJ ~ ~ C (~ ~J eD Q t~
G
a~ c~
C C _~
Q~ o N aJ N a~ ~ ~
~1 C C ~ ~ C c c C ~o C c ~ c c c C c C c c c
~ .C~1 ~I d ~rJ rl ~ ~ rl ~ ~d ~d ~ ~ ~.~ d d ~d ,~
~ c ~ J ~ ~ ~ 'e ~E ~ C n ~ JC r r J- ~ r o
O U :~ O E E t~ ~ O O O :~ u ~ O O ~ O O o o o o o c
0 ~ ~ C N O O t:L CL N N N C 1~ 1 ~ N tJ N N N N N t . C
C ~ C L ~ C 0 'D d ~rl C C C GJ ~ _~ C C ~ C C C C c c c r a~
E lo c ~ c c c c ~ a~ ~ c ~ ~ ~ ~ ~ ~ ~ G) ~ ~ ~ c) c c
U o ~ ~ c. o ~ m Q ~ Q Q ~0 Q Q ~ C:l C
U
CL,
~
X ~ ~ ~ ~ N ~ .- U7 ~ O _ ~ O .~ ~ rJ C. O --
~:~ ~ _ N N N N N t~ N N N N 0 rl r7 r7 Q Q r7 01 0 Q _ _
i3
~ 15- O.Z. 0050/3a3aO
E
~ o o o o o o o
O O O 11 1 10 t- Q
o _ _ _ _ _ _ _
~c O O O O O O
O O O U~
O O O O O O O
~_ O crl O
_ _ _ _ _ _
O O O O O O O
O O~ O ~-I r-7 1~1 U7
.,
_ O O O O O O U~
O O O O O O O
O O O O O O O
-- O
Ct~ ~rl
O
::~ E r ~ O~. .. O
~1 o a~ ,~
~¢ ~ L;3 ~O
u~
c
E ~6 u
a~
.~
C C C CC C C
c o o ~7 oo o o
a~ 5 ~ c
rl C~ C C C 1 C C C :~
J~ E
O O c c c cr c c
~o
. E~
~ rt~ oc~ E-
~ ~ 3~33S3
- 16 - O.Z~ 0050/38380
E~AMPLE S0
Examples 18, 19 and 20 were repeated on an injec-
tion molding machine at a die temperature of 130C.
Tablets consisting of solid solutions were obtained.
S EXAMPLE 51
Yitamin C, as the active compound, was mixed in
a weight ratio of 1:1 w;th the following NVP polymers in a
twin-screw extruder, the mixture was extruded at the tem-
peratures stated in the Table for shots 1 to 6 and for the
die, and the extrudate was shaped into tablets via a
calender, according to the parallel German Application
P 36 12 211.4.
a) Copolymer of 60X by ~eight of NVP and 40% by weight of
vinyl acetate; K value about 33.
b) 90~ by weight of copolymer (a) and 10% by weight of
stearyl alcohol.
c) Homopolymer of NVP; K value 17.
T1 T2 T3 T4 T5 T6Die
a) 60 80 100 110 120 120120C
20 b) 60 80 80 100 100 110110C
c) 60 80 100 110 120 120125C
In all three cases, the vitamin was liberated in
water in the course of from 1 to Z hours. During the pro-
cessing described, it did not undergo any decomposition
at all and, in this form~ was protected from the effects
of light and atmospheric oxygen when stored for a pro-
longed period.
